Monoclonal antibody against interleukin-13 receptor alpha 1 (IL-13Ra1)
The present invention relates generally to antibodies that bind to the Interleukin-13 receptor α1 chain (IL-13Rα1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13Rα1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13Rα1/ligand interaction is also provided.
1. An isolated monoclonal antibody 1D9 produced by the hybridoma deposited at the European Collection of Cell Cultures (ECACC) under Accession No. 03032101, or an antigen-binding fragment thereof.
2. An isolated monoclonal antibody, or an antigen-binding fragment thereof, which binds to the IL-13Rα1 chain as set forth in SEQ ID NO: 4 and antagonizes IL-13 receptor-mediated signaling by IL-13 and IL-4, said antibody or fragment comprising:
(i) a heavy chain variable region which comprises SEQ ID NO: 28 or SEQ ID NO: 26, or
(ii) a light chain variable region which comprises SEQ ID NO: 27 or SEQ ID NO: 25.
3. An isolated monoclonal antibody, or an antigen-binding fragment thereof, which binds to the IL-13Rα1 chain as set forth in SEQ ID NO: 4 and antagonizes IL-13 receptor-mediated signaling by IL-13 and IL-4, said antibody or fragment comprising a heavy chain variable region which comprises the 3 CDR sequences of monoclonal antibody 1D9 from SEQ ID NO: 28, and a light chain variable region which comprises the 3 CDR sequences of monoclonal antibody 1D9 from SEQ ID NO: 27.
4. The antibody or fragment of claim 3 , wherein said heavy chain variable region comprises SEQ ID NO: 26.
5. The antibody or fragment of claim 3 , wherein said light chain variable region comprises SEQ ID NO: 25.
6. The antibody of claim 3 , wherein the antibody is a humanized antibody.
7. The antibody or fragment of claim 3 , wherein the 3 CDR sequences of monoclonal antibody 1D9 from SEQ ID NO: 28 and the 3 CDR sequences of monoclonal antibody 1D9 from SEQ ID NO: 27 are grafted into a human framework or a human consensus framework.
8. The antibody or fragment of claim 7 , wherein said heavy chain variable region comprises SEQ ID NO: 26, and said light chain variable region comprises SEQ ID NO: 25.
9. An isolated antibody according to any one of claims 2 - 7 , comprising a constant region of a human antibody.
10. An isolated monoclonal antibody, or antigen-binding fragment thereof, which competes with the 1D9 antibody produced by the hybridoma deposited at the European Collection of Cell Cultures (ECACC) under Accession No. 03032101 for binding to the IL-13Rα1 chain as set forth in SEQ ID NO: 4, and binds to the same epitope in said IL-13Rα1 chain as said 1D9 antibody, wherein said antibody or antigen-binding fragment thereof antagonizes IL-13 receptor-mediated signaling by IL-13 and IL-4.
11. The monoclonal antibody of claim 10 , wherein said monoclonal antibody is a chimeric, human, or humanized antibody.
12. A composition comprising an antibody or an antigen-binding fragment thereof according to any one of claim 2 - 8 , 10 or 11 , and a pharmaceutically acceptable carrier.